Articles

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Memorial Sloan Kettering Cancer Center, New York, NY, USA
John Hopkins University, Baltimore, MD, USA
University of Nebraska Medical Center, Omaha, NE, USA
Tower Cancer Research Foundation, Beverly Hills, CA, USA
University of Colorado Cancer Center, Aurora, CO, USA
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Syndax Pharmaceuticals, Inc., Waltham, MA, USA
Syndax Pharmaceuticals, Inc., Waltham, MA, USA
Syndax Pharmaceuticals, Inc., Waltham, MA, USA
Syndax Pharmaceuticals, Inc., Waltham, MA, USA
MD Anderson Cancer Center, Houston, TX, USA
Roswell Park Cancer Institute, Buffalo, NY, USA, USA
Memorial Sloan Kettering Cancer Center, New York, NY, USA;MD Anderson Cancer Center, Houston, TX, USA
Vol. 101 No. 8 (2016): August, 2016 https://doi.org/10.3324/haematol.2016.142406